Table 3.
Organoids in clinical trials.
| Organ | NCT Number | Study Title | Study Status | Conditions | Study Objective |
|---|---|---|---|---|---|
| Liver | NCT05183425 | Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis | Recruiting | Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases | Evaluate consistency of drug sensitivity of primary tumor and its matched liver metastasis |
| Pancreas | NCT04777604 | Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Organoid | Not yet recruiting | Pancreas Cancer | Survival rate of pancreatic cancer patients after they were started adjuvant chemotherapy |
| NCT04736043 | Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid | Recruiting | Pancreatic Cancer Resectable | Overall survival rate after adjuvant chemotherapy for pancreatic cancer was started | |
| NCT05351983 | Patient-derived Organoids Drug Screen in Pancreatic Cancer | Recruiting | Pancreas Cancer |Pancreas Neoplasm|Pancreas Adenocarcinoma|Pancreatic Cancer|Pancreatic Neoplasms|Pancreatic Adenocarcinoma |
Feasibility of patient-derived organoids that can be successfully used for drug screening | |
| NCT04931381 | Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer | Recruiting | Advanced Pancreatic Cancer | Measure patient response to cancer treatment, complete response (CR), partial response (PR), or stable disease (SD) | |
| NCT04931394 | Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer | Recruiting | Pancreatic Cancer | Radiology assessment of response to adjuvant therapy | |
| NCT05842187 | In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer | Recruiting | Pancreatic Cancer|Gastric Cancer | Analyze PFS (Progressive-free survival) from initiation of treatment to the occurrence of disease progression or death | |
| Brain | NCT05772741 | Grafts of GSCs Into Brain Organoids for Testing Anti-invasion Drugs | Recruiting | Glioblastoma|Glioma, Malignant | Study anti-invasive drugs against invasive glioma stem cells co-cultured with brain organoids |
| Kidney | NCT04342286 | To Establish a Reproducible Organoid Culture Model with Human Kidney Cancer | Completed | Kidney Cancer | Establishment of patient-derived kidney tumor organoids with phenotypic stability |
| Intestine | NCT04497727 | Gut Organoid Study | Active, not recruiting | Gut Inflammation | Gut–microbiota interaction in hypertensive and normotensive reference subjects |
| NCT03256266 | Effect of Antigens or Therapeutic Agents on in Vitro Human Intestinal Organoids | Recruiting | Intestine Disease | Gluten peptide provocation to determine proliferation, apoptosis, histology, and cytokine expression | |
| NCT05294107 | Intestinal Organoids | Recruiting | Digestive System Diseases |Inflammatory Bowel Disease, Ulcerative Colitis Type|Crohn Disease | Patient-derived organoids cultured on 3D matrix gel for molecular screening to assess the effects of intestinal stress and healing | |
| NCT02874365 | Intestinal Stem Cells Characterization | Recruiting | Inflammatory Bowel Diseases | Generation of organoid models for stem cell characterization | |
| NCT05832398 | Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer | Recruiting | Colorectal Cancer | Organoid generation for drug screening | |
| NCT05425901 | Preclinical Evaluation of Multimodal Therapeutic Strategies in Intestinal Irradiation and Inflammatory Bowel Disease from Organoids | Not yet recruiting | Radiation Enteritis|Inflammatory Bowel Diseases | Optimize organoid generation to mimic human intestine by performing scRNA-seq | |
| NCT04371198 | Patient-Derived Organoids for Rectal Cancer | Completed | Rectum Cancer | Patient-derived organoid to study rectal cancer | |
| NCT04996355 | Organoids-on-a-chip for Colorectal Cancer and in Vitro Screening of Chemotherapeutic Drugs | Recruiting | Colorecta l Neoplasms|Organoids | Chemotherapeutic drug screening based on organoid chips to predict the effect of chemotherapy against Colorectal cancer | |
| NCT05352165 | The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer | Not yet recruiting | Neoadjuvant Therapy | Neoadjuvant therapy in organoids | |
| NCT05183425 | Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis | Recruiting | Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases | Organoids in testing drug sensitivity to primary tumor and its matched liver metastasis | |
| NCT05304741 | The Culture of Advanced/Recurrent/Metastatic Colorectal Cancer Organoids and Drug Screening | Recruiting | Colorectal Cancer | Generate patient-derived organoids to evaluate overall survival | |
| NCT04906733 | Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients. | Recruiting | Colon Cancer|Organoids|Metastatic Cancer | Association of drug sensitivity tests in patient-derived organoids and clinical outcomes | |
| Lungs | NCT04859166 | Prospective Primary Human Lung cancer Organoids to Predict Treatment Response | Completed | Lung Cancer | To successfully establish PDX model and biobanks of lung cancer organoids and determine the frequency of primary, secondary, and tertiary organoid formation |
| NCT05669586 | Organoids Predict Therapeutic Response in Patients with Multi-line Drug-resistant Non-small Cell Lung Cancer | Recruiting | Lung Cancer|Organoid|NSCLC | Generate non-small cell lung cancer organoids to predict therapeutic response in multi-drug resistant cancer and evaluate progression-free survival | |
| NCT03655015 | Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer | Recruiting | Lung Neoplasm | Establish biobank of patient-derived organoids (PDOs) to recapitulate ex vivo responses observed clinically | |
| NCT05092009 | Lung Cancer Organoids and Patient-Derived Tumor Xenografts | Recruiting | Lung Cancer | Generate normal and patient tumor-derived organoids for long-term culture and bio-banking | |
| NCT03979170 | Patient-derived Organoids of Lung Cancer to Test Drug Response | Recruiting | Lung Cancer|Organoid | Establish patient-derived organoids that are phenotypically and genetically identical to the source tumor | |
| NCT05136014 | Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients with EGFR Mutation in a Patient-derived Organoid Model | Enrolling by invitation | Lung Cancer|Lung Adenocarcinoma|EGFR Activating Mutation| KRAS Mutation-Related Tumors|Non-Small Cell Lung Cancer | In vivo evaluation of osimertinib alone or in combination in patient-derived organoids | |
| Gastric | NCT05842187 | In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer | Recruiting | Pancreatic Cancer|Gastric Cancer | Pancreatic and gastric metastatic cancer organoids to study drug sensitivity and PFS (Progressive-free survival) |
| NCT05652348 | Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer | Recruiting | Gastric Cancer|Colon Cancer|Peritoneal Carcinomatosis | Ex vivo response to dose dependent chemotherapeutic agents in organoid models | |
| NCT05351398 | The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer | Not yet recruiting | Advanced Gastric Carcinoma | Determine clinical efficacy based on studies in advanced gastric cancer organoids by evaluating Objective Response Rate (ORR) | |
| NCT05203549 | Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric Cancer | Recruiting | Gastric Cancer | Establish and optimize generation of patient-derived organoids from gastric cancer tumors |
Data taken from clinicaltrials.org *. Patient-derived organoids can identify patient-specific drug targets and thus work as a tool for personalized medicine. Links to the studies can be found in Supplementary Table S1. * URL last accessed on 20 October 2023.